x
Pulmonary edema is a serious medical condition in which excess fluid accumulates in the lungs, impairing gas exchange and causing difficulty in breathing. It can be cardiogenic, due to heart failure, or non-cardiogenic, arising from lung injury, infection, trauma, or toxic exposure. According to Stellar Market Research, the global pulmonary edema market was valued at approximately USD 6.6 billion in 2024 and is forecast to grow at a CAGR of 7.8% from 2025 to 2032, reaching nearly USD 12.04 billion by 2032.
Request Free Sample Report:https://www.stellarmr.com/report/req_sample/pulmonary-edema-market/2673
Key factors driving the growth of the pulmonary edema market include:
Rising Cardiovascular Disease (CVD) Prevalence: Heart disease is one of the primary causes of cardiogenic pulmonary edema. With increasing global rates of heart failure, coronary artery disease and hypertension, more patients are at risk.
Growing Incidence of Trauma and Accidents: Road accidents and chest injuries contribute significantly to non-cardiogenic pulmonary edema, creating acute treatment demand.
Aging Population: As the population ages, comorbid conditions (heart disease, kidney issues) that predispose individuals to pulmonary edema become more common.
Innovative Therapies: Advances in drugs — for example, combinations such as sacubitril/valsartan — and novel therapeutics (e.g., synthetic peptides) are improving outcomes.
Improved Diagnostics: Enhanced diagnostic tools, including imaging (CT, ultrasound) and deep-learning–assisted lung evaluation, are helping earlier detection and management.
These drivers create strong opportunities for pharmaceutical companies, medical technology firms, and healthcare providers to invest in treatments, diagnostics, and long-term care solutions for pulmonary edema.
Several emerging trends are expected to shape the pulmonary edema market in the coming years:
Precision Therapies & Peptide-Based Drugs: Newer molecules like synthetic peptides (such as solnatide) are being developed to more precisely manage fluid accumulation in the lungs.
Repurposing Existing Drugs: Drugs currently used for heart failure (e.g., sacubitril/valsartan) are being more widely adopted or optimized to prevent or manage pulmonary edema.
Growth in Diagnostic Imaging: Lung ultrasound combined with AI and deep learning is emerging as a powerful tool in assessing and monitoring pulmonary edema severity.
Expansion of Healthcare Infrastructure: In emerging markets, expanding hospital capacity, better access to intensive care, and growing awareness will drive demand for pulmonary edema treatment.
Regenerative and Device-Based Support: As treatment paradigms evolve, there may be more integration of device-based support (ventilation) with pharmacological therapy.
Risks remain, including regulatory hurdles for new drugs, high costs for R&D, and inequalities in access to advanced diagnostics.
The report breaks down the pulmonary edema market as follows:
By Disease Type:
Cardiogenic Pulmonary Edema (driven primarily by heart failure)
Non-Cardiogenic Pulmonary Edema (caused by lung injury, infection, trauma, or altitude)
By Diagnosis Type:
Imaging Techniques (chest X-ray, CT scans, lung ultrasound)
Laboratory Tests (blood gas analysis, biomarkers)
By Treatment Type:
Oxygen Therapy (supplemental oxygen)
Medications (diuretics, vasodilators, heart failure drugs)
Surgical Interventions (e.g., valve repair, bypass grafting)
By End User:
Hospitals & Clinics
Academic / Research Institutes
Ambulatory Surgical Centers
By Region:
North America (dominant)
Europe, Asia-Pacific, Middle East & Africa, South America
This insightful segmentation helps stakeholders target high-growth areas such as cardiogenic edema treatment or imaging-based diagnosis in specific geographies.
North America: The region leads the pulmonary edema market. Its strong healthcare infrastructure, higher incidence of cardiovascular diseases, and advanced ICU and diagnostic capabilities make it a key market.
Asia-Pacific: This region is projected to grow strongly due to increasing cardiovascular disease prevalence, rising healthcare investment, a growing elderly population, and improving access to advanced diagnostics and therapies.
These regional insights suggest that while developed markets will continue to drive revenue, emerging markets will be critical for future volume growth and therapy adoption.
From a user (“commutator”) perspective — including patients, healthcare providers, and payers — the following apply:
Patients: Individuals with heart failure or acute lung injury are primary consumers. They benefit from rapid diagnosis and effective therapies that reduce fluid in the lungs and improve breathing.
Healthcare Providers: Hospitals, intensive care units, and cardiology / pulmonary departments prioritize fast, reliable diagnostic tools and therapeutics that can improve patient outcomes and reduce hospital stay durations.
Payers / Insurers: They are increasingly interested in cost-effective therapies that reduce readmission rates, manage chronic heart conditions, and optimize resource utilization in hospitals.
Challenges for Users: High treatment costs, need for long-term therapy, infrastructure demands (imaging, ICU), and access to novel therapies can limit adoption; trust and awareness in newer therapeutic agents also are issues.
Providers that offer integrated solutions — combining diagnostics, advanced therapeutics and care pathways — will provide the greatest value.
In conclusion, the Pulmonary Edema Market is poised for strong growth, from USD 6.6 billion in 2024 to around USD 12.04 billion by 2032, driven by a rising burden of cardiovascular disease, innovation in diagnostics and treatment, and expanding healthcare access. As cardiogenic edema remains the largest-segment, the growth of novel therapeutics, diagnostic imaging, and hospital-based care aligns with evolving clinical needs.
For pharmaceutical companies, investors, and healthcare providers, the market presents significant opportunity: developing and scaling effective, targeted therapies, rolling out advanced diagnostic technology, and optimizing care pathways can drive both clinical impact and business value.
Pulmonary edema is a critical yet addressable condition — and the coming years may redefine how this life-threatening syndrome is diagnosed, treated, and managed globally.
About us
Phase 3,Navale IT Zone, S.No. 51/2A/2,
Office No. 202, 2nd floor,
Near, Navale Brg,Narhe,
Pune, Maharashtra 411041
sales@stellarmr.com
